Bispecific antibodies (bsAbs) possess unique advantages due to their ability to simultaneously target two distinct antigens, which helps to enhance the immune system's recognition and killing of tumor cells.
In January, Jiangsu Hengrui Pharmaceuticals' Tegileridine Fumarate injection, for treating moderate to severe post-op abdominal pain, was approved in China.
In February, University of Leicester and Leicester Diabetes Centre experts published a summary of obesity treatments in "International Journal of Obesity," highlighting new drugs inspired by gut incretin hormones.
This article provides an interpretation of a review published in the 2021 issue of "Nature Reviews Drug Discovery", which analyzes the history and trends of peptide drug development over the past 100 years.
Upadacitinib acts as an ATP-competitive JAK inhibitor; it competes with ATP and blocks nucleotide binding to inhibit kinase activity and the phosphorylation of downstream effectors.